YOU ARE HERE:
Salvage treatment news
page  of 5
 
Headline
Date
  Once-daily darunavir/ritonavir may be an option for some treatment-experienced patients
30.10.08
  Etravirine (TMC125, Intelence) granted accelerated approval in US
21.01.08
  Triple-class failure emerges slowly in UK patients
07.12.07
  Start treatment when CD4 cell count is 350, say revised US guidelines
05.12.07
  Bevirimat 300mg oral solution dose does well in study
26.10.07
  Undetectable viral load is goal for all, together with earlier treatment, say new European treatment guidelines
25.10.07
  Raltegravir receives accelerated approval from the FDA
15.10.07
  Roche abandon Biojector 2000 for T-20 administration
04.10.07
  Most patients on incompletely suppressive therapy maintain CD4 counts and stable viral loads
04.10.07
  ICAAC: 48-week results show maraviroc still potent in highly treatment-experienced
20.09.07
  ICAAC: Raltegravir shows sustained effect in highly treatment-experienced patients
19.09.07
  ICAAC: Vicriviroc safe, effective after 2 years, phase III studies start soon
19.09.07
  ICAAC: Best response to elvitegravir seen when used with T-20 and other active agents
19.09.07
  T-20 increases tipranavir levels but does not increase risk of liver side-effects
12.09.07
  IAS: Maraviroc produces best results when combined with another active drug
14.08.07
  TMC-125 and darunavir show strong effect in highly treatment-experienced, even without T-20
06.07.07
  Merck hopes for US integrase inhibitor license by October
28.06.07
  Is there any clinical benefit to staying on a failing regimen?
13.04.07
  Darunavir looking promising as companion for agents in new HIV drug classes
05.04.07
  Next generation NRTI, apricitabine (ATC), shows early promise
19.03.07

page  of 5